Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Hereditary angioedema.

Michael M Frank¹

¹Department of Pediatrics, Duke University Medical Center, North Carolina 27710, USA. frank007@mc.duke.edu

Current Opinion in Pediatrics

|November 12, 2005

Summary

This summary is machine-generated.

Hereditary angioedema, a condition often missed in childhood, involves C1-inhibitor deficiency. New therapies show promise for managing acute attacks and improving treatment options for this potentially fatal illness.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema.

The journal of allergy and clinical immunology. In practice·2020

Same author

Complement activation by IgG containing immune complexes regulates the interaction of C1q with its ligands.

Molecular immunology·2019

Same author

Management of Children With Hereditary Angioedema Due to C1 Inhibitor Deficiency.

Pediatrics·2016

Same author

Safety and Usage of C1-Inhibitor in Hereditary Angioedema: Berinert Registry Data.

The journal of allergy and clinical immunology. In practice·2016

Same author

Practice parameter for the diagnosis and management of primary immunodeficiency.

The Journal of allergy and clinical immunology·2015

Same author

Before and after, the impact of available on-demand treatment for HAE.

Allergy and asthma proceedings·2015

Same journal

Childhood sleep disorders: practical management for the pediatrician.

Current opinion in pediatrics·2026

Same journal

Advanced therapies in management of pediatric inflammatory bowel disease.

Current opinion in pediatrics·2026

Same journal

Artificial intelligence in pediatric endoscopy for hereditary polyposis syndromes: promises and challenges.

Current opinion in pediatrics·2026

Same journal

Hormonal acne therapies in pediatrics.

Current opinion in pediatrics·2026

Same journal

Clinical implementation of artificial intelligence in adolescent mental healthcare.

Current opinion in pediatrics·2026

Same journal

Advances in the treatment of pediatric hidradenitis suppurativa: emerging therapies and future directions.

Current opinion in pediatrics·2026

See all related articles

Area of Science:

Immunology
Genetics
Pharmacology

Background:

Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling.
It is caused by a deficiency or dysfunction of the plasma protein C1-inhibitor, leading to dysregulation of the kinin-kallikrein pathway.
Diagnosis is often delayed due to overlapping symptoms with other conditions, particularly in childhood.

Purpose of the Study:

To review the current understanding of hereditary angioedema, including its clinical presentation and pathophysiology.
To discuss the emerging therapeutic landscape for managing acute attacks of HAE.
To highlight the importance of recognizing HAE and understanding available treatment options.

Main Methods:

Review of current literature on hereditary angioedema.

Related Experiment Videos

Analysis of the pathophysiology focusing on the bradykinin pathway.

Overview of ongoing and planned clinical trials for HAE treatments.

Main Results:

Hereditary angioedema is frequently misdiagnosed or overlooked in pediatric patients.
The central role of the kinin-generating pathway and bradykinin in edema formation is increasingly recognized.
Multiple novel therapeutic agents for acute HAE attacks are demonstrating promising results in clinical trials.

Conclusions:

Effective chronic management strategies for HAE exist, but challenges remain, especially for pediatric use.
The development of targeted therapies for acute HAE attacks is anticipated to significantly improve patient outcomes.
Early recognition of HAE clinical manifestations and awareness of therapeutic options are crucial for managing this potentially life-threatening condition.